An in-vivo administration device

Abstract

The application discloses an in-vivo drug delivery device, and relates to the technical field of medical intervention instruments.The main body of the in-vivo drug delivery device is made of PEG powder and 50:50 proportion of PLGA medical degradable high-molecular material, is formed through a salt pore forming process, and is internally provided with uniform and slow-release pores.The size can be adapted to different target blood vessels, the device is implanted into a lesion blood-supplying blood vessel through an intervention mode, and the drug loading formula can be flexibly adjusted according to diseases, and heparin and dexamethasone are added to prevent thrombosis and suppress inflammation.The in-vivo drug delivery device can realize 1-3 month controllable slow release of drugs, accurately delivers the drugs to a lesion at a high concentration, solves the problems of poor curative effect and large toxic and side effects of systemic drug delivery, is suitable for local treatment of malignant tumors and refractory chronic inflammation, and finally is completely degraded without residue, and does not need secondary operation.The in-vivo drug delivery device has the advantages of simple structure, flexible drug loading, good biocompatibility, wide clinical application range, and effectively makes up for the technical defects of existing local drug delivery devices.

Description

Technical Field

[0001] This invention relates to the field of interventional diagnostic and therapeutic devices, and more particularly to an in vivo drug delivery device. Background Technology

[0002] In clinical disease treatment, malignant tumors and chronic refractory inflammation have always been challenging to treat. Current mainstream treatments mostly employ systemic chemotherapy, systemic anti-inflammatory drug delivery, conventional stent implantation, and surgical resection, but all have significant technical limitations: When administering drugs systemically, after absorption in the gastrointestinal tract, metabolism in the liver, and distribution through systemic blood circulation, the effective concentration that actually reaches the lesion site is extremely low, making it difficult to achieve the ideal therapeutic effect. At the same time, excessive drugs can damage normal tissues and organs, causing serious systemic toxic side effects. Conventional vascular stents only provide physical support or short-term release of a single drug, and cannot achieve long-term, controllable, and high-concentration local drug delivery. Moreover, most stents need to remain in the body for a long time, which can easily lead to complications such as thrombosis, restenosis, and rejection. Existing biodegradable drug delivery devices have problems such as unreasonable material ratios, mismatch between degradation and drug release rates, single drug loading formulations, and limited applicability to different diseases. They cannot flexibly adjust drug components according to different disease types, making it difficult to meet the diverse local precision treatment needs in clinical practice.

[0003] To address the shortcomings of the existing technologies, this invention provides an in vivo drug delivery device. By optimizing the material system and preparation process, it achieves long-term, controllable, and sustained drug release. At the same time, it allows for flexible adjustment of the drug delivery formula according to the symptoms, precisely adapting to the local treatment needs of different diseases. This effectively solves the technical problems of poor efficacy, significant toxic side effects, and limited functionality of traditional devices. Summary of the Invention

[0004] Purpose of the invention: This invention discloses an in vivo drug delivery device, which belongs to the category of interventional biodegradable targeted drug delivery devices, aiming to solve the technical problems of poor local drug delivery effect, uncontrollable drug release, single drug loading formula, and limited applicable diseases in the prior art.

[0005] Technical solution: An in vivo drug delivery structure, comprising: a carrier structure for carrying a substance, and a release structure for releasing the substance; the structure is suitable for implantation or placement in at least one human or animal body.

[0006] Furthermore, it aims to solve the technical problems of poor local drug delivery, uncontrollable drug release, single drug delivery formula, and limited applicable diseases in existing technologies.

[0007] Furthermore, the main body of the in vivo drug delivery device is prepared by blending PEG powder with PLGA medical biodegradable polymer material in a 50:50 ratio and processed by salt pore-forming technology. The internal structure of the in vivo drug delivery device forms a uniformly distributed sustained-release pore structure, ensuring stable and continuous drug release. The size of the in vivo drug delivery device can be precisely adapted to different target blood vessel anatomy specifications. It is pushed into the blood vessel supplying the lesion through interventional minimally invasive methods, and is fixed in place against the wall without the risk of displacement or dislodgement.

[0008] Furthermore, the in vivo drug delivery device carries a compound drug system, and the drug formulation can be flexibly adjusted according to the target disease. For tumor-related diseases, it can be adapted to anti-tumor compound drugs, and for chronic refractory inflammation, it can be adapted to anti-inflammatory and analgesic drugs. At the same time, heparin and dexamethasone are added. Heparin is used to prevent thrombosis in blood vessels after implantation of the in vivo drug delivery device, and dexamethasone is used to inhibit local tissue inflammation and reduce adverse reactions after implantation.

[0009] Furthermore, this in vivo drug delivery device relies on the degradation characteristics of the polymer material itself to achieve controlled sustained release of drugs for 1 to 3 months. After implantation, the drug is delivered to the lesion area in a high concentration and with precision. The ideal therapeutic effect can be achieved without systemic drug administration. The in vivo drug delivery device gradually and completely degrades in the body. The degradation products are non-toxic and harmless, and there are no foreign body residues in the end, so there is no need for a second surgery to remove it.

[0010] Beneficial effects: Targeted drug delivery has outstanding effects: Direct implantation into the blood vessels supplying the lesion allows the drug to act precisely on the lesion site, resulting in a local drug concentration that is much higher than that of systemic drug delivery. This completely solves the core problem of insufficient lesion concentration and ineffective treatment when administered systemically, and significantly improves the treatment effect of tumors and refractory inflammation.

[0011] Controllable drug release and material degradation: By using biodegradable polymer materials in a specific ratio and combining them with salt pore-forming technology, a stable sustained release of drugs can be achieved over 1 to 3 months. The degradation rate matches the drug release rate, avoiding sudden release or interruption of sustained release and ensuring the continuity of treatment.

[0012] The drug delivery system is flexible and versatile: the drug components can be specifically adjusted according to the different treatment needs of malignant tumors such as pancreatic cancer and liver cancer, or refractory inflammations such as chronic pancreatitis and intractable pelvic inflammatory disease, breaking through the limitations of a single indication and applicable to a wide range of diseases.

[0013] Excellent biocompatibility and few complications: The addition of heparin and dexamethasone has a synergistic effect, effectively preventing thrombosis and local inflammation. The material does not cause rejection by the body, avoiding the complications of long-term indwelling traditional stents, while significantly reducing the toxic side effects such as liver and kidney damage and gastrointestinal discomfort caused by systemic medication.

[0014] Minimally invasive implantation with high patient compliance: It is compatible with routine clinical interventional surgery procedures, and is implanted through a minimally invasive method without the need for open surgery. The in-body drug delivery device is completely degraded and does not need to be removed a second time, reducing patient pain and surgical risks, and has strong clinical applicability.

[0015] The process is simple and the scope of protection is broad: the preparation process is clear and the core parameters do not need to be fully disclosed, which not only meets the requirements for sufficient patent disclosure, but also avoids the technology from being easily imitated. At the same time, it expands the scope of patent protection by relying on flexible drug loading and universal structure. Attached Figure Description

[0016] Figure 1 This is a schematic diagram of the overall structure of the present invention. Detailed Implementation

[0017] To make the technical solution of the present invention clearer, the present invention will be further described in detail below with reference to the accompanying drawings and specific embodiments.

[0018] Example 1 like Figure 1 As shown, Example 1 provides local chemotherapy for pancreatic cancer. This embodiment is a specific implementation plan for local chemotherapy administration in pancreatic cancer and does not limit the scope of patent protection.

[0019] In this embodiment, the in vivo drug delivery device is adapted for gastroduodenal artery interventional implantation. The main body of the in vivo drug delivery device is prepared by blending PEG powder with PLGA medical biodegradable polymer material in a 50:50 ratio, and is processed by salt pore-forming process to form a uniform sustained-release pore structure inside the in vivo drug delivery device, ensuring stable drug release.

[0020] The in vivo drug delivery device is precisely sized to fit the gastroduodenal artery: 3cm in length and 3mm in diameter, allowing for precise placement and fixation within the artery via an interventional catheter. The device contains a complex drug system, with the drugs listed in descending order of concentration: berberine, tetrahydrocurcumin, quercetin, rapamycin, and AS1411. Heparin and dexamethasone are also added, for the prevention of thrombosis and the inhibition of local inflammation, respectively.

[0021] The in vivo drug delivery device achieves controlled sustained release over 1-3 months through material degradation, delivering high concentrations of drugs to the pancreatic tumor area and solving the problems of insufficient systemic chemotherapy drug concentration and high toxic side effects. The in vivo drug delivery device eventually degrades completely without leaving any foreign matter, eliminating the need for a second surgery to remove it.

[0022] The drug formulation contained in this device can be flexibly adjusted according to the target symptoms and disease type, and can be specifically adapted to the treatment needs of different diseases.

[0023] Example 2 This example illustrates a local chemotherapy administration regimen for liver cancer.

[0024] The in vivo drug delivery device described in this embodiment has the same material composition and manufacturing process as in Embodiment 1, but the drug system can be adjusted according to the needs of liver cancer treatment. The in vivo drug delivery device is sized to fit the proper hepatic artery: 5cm in length and 5mm in diameter.

[0025] During use, the in vivo drug delivery device is pushed into the proper hepatic artery via an interventional catheter and fixed therein. The in vivo drug delivery device degrades and releases the drug within 1 to 3 months, targeting the liver cancer lesion. This solves the problems of poor targeting and large side effects of systemic drug delivery, while preventing thrombosis and inflammatory reactions, and eventually completely degrades.

[0026] Example 3 This embodiment is used for local high-concentration anti-inflammatory treatment of refractory chronic pancreatitis.

[0027] The in vivo drug delivery device described in this embodiment has the same structure and materials as in Embodiment 1. The drug formulation can be adjusted according to the anti-inflammatory and analgesic needs of chronic pancreatitis, while retaining heparin and dexamethasone. The in vivo drug delivery device is sized to fit the gastroduodenal artery: 3cm in length and 3mm in diameter.

[0028] When systemic medication is used for this condition, the local drug concentration in the pancreas is extremely low, resulting in poor efficacy of conventional treatments. By implanting an intra-arterial drug delivery device into the pancreatic artery via interventional procedures, the device continuously releases high concentrations of anti-inflammatory drugs for 1-3 months, directly targeting the inflamed lesions. This significantly improves intractable inflammation and pain, solving the clinical challenge of ineffective systemic drug delivery.

[0029] Example 4 This embodiment is used for the local treatment of refractory chronic pelvic inflammatory disease in women.

[0030] The in vivo drug delivery device described in this embodiment has the same structure and materials as in Embodiment 1. The anti-inflammatory and antibacterial drug formulation can be adjusted according to the characteristics of pelvic inflammatory disease, while retaining heparin and dexamethasone. The in vivo drug delivery device is sized to fit the uterine artery: 2cm in length and 2.5mm in diameter.

[0031] Systemic medication is often ineffective in achieving local concentrations for refractory pelvic inflammatory disease, leading to frequent relapses and difficulty in complete cure. By implanting an internal drug delivery device into the pelvic artery, local drug concentrations are significantly higher than with systemic administration, allowing for long-term stable control of inflammation, substantial reduction in recurrence rates, and avoidance of the side effects associated with systemic medication.

[0032] Example 5 This embodiment is used for the treatment of refractory chronic soft tissue inflammation around the hip and knee joints.

[0033] The in vivo drug delivery device described in this embodiment has the same structure and materials as that in Embodiment 1. The drug formulation can be adjusted according to the needs of anti-inflammatory and swelling reduction, while retaining heparin and dexamethasone. The in vivo drug delivery device is sized to fit the femoral artery branch or the descending genu artery: 2.5 cm in length and 2 mm in diameter.

[0034] For deep joint inflammation, conventional oral and topical medications often fail to penetrate effectively, resulting in poor treatment outcomes. By implanting an interventional device into the supplying artery, a high-concentration drug delivery system can deliver sustained-release medication directly to the lesion, continuously suppressing stubborn inflammation and reducing swelling, eliminating the need for long-term systemic medication.

[0035] Example 6 This embodiment is used for the local treatment of refractory tumors and chronic intractable inflammation in companion animals such as dogs and cats.

[0036] The in vivo drug delivery device described in this embodiment has the same structure, materials, and manufacturing process as in Embodiment 1. The drug formulation can be flexibly adjusted according to the animal's disease, weight, and lesion location. The size of the in vivo drug delivery device is adapted to the size of the animal's target blood vessels and can be implanted into the blood supply artery of the animal's tumor or the blood supply vessel of the chronic inflamed area.

[0037] For diseases in animals that are difficult to treat surgically, have significant side effects from systemic medication, or have insufficient local drug concentrations, a minimally invasive interventional approach can be used to implant an internal drug delivery device. This allows for long-term, stable, and high-concentration local drug delivery for 1 to 3 months, improving the cure rate of animal diseases, reducing suffering, and minimizing systemic toxicity. The internal drug delivery device is eventually degraded and absorbed, eliminating the need for a second surgery to remove it.

[0038] The embodiments described above are merely illustrative of several implementations of the present invention, and while the descriptions are specific and detailed, they should not be construed as limiting the scope of the present invention. It should be noted that those skilled in the art can make various modifications and improvements without departing from the concept of the present invention, and these modifications and improvements all fall within the scope of protection of the present invention. Therefore, the scope of protection of this patent should be determined by the appended claims.

Claims

1. An in vivo drug delivery structure, characterized in that, include: A support structure for carrying a substance, and a release structure for releasing the substance; The structure is suitable for interventional implantation or placement in at least one human or animal body.

Images